large-Scale clinical trials of antiviral drug ramdevpir confirm its effectiveness in the fight against coronavirus infection Covid-19.

the Study continues until only announced its preliminary results. However, they were convincing enough for the national Institute of Allergy and infectious diseases USA (NIAID) released on this occasion a special statement confirming the efficacy of the drug.

“Data show that the unambiguous ramdevpir has a significant positive effect, accelerating recovery,” — told reporters the head of the NIAID, Anthony Fauci.

In the experiment, which began over two months ago, on 21 February, attended by more than 1,000 patients from the United States, Asia and Europe with confirmed diagnosis Covid-19.

the Researchers used the method of double blind testing: the patients divided into two groups, one of which patients receive ramdevpir (in addition to the usual symptomatic treatment) and the other with placebo. At the same time in which of the groups is a particular patient, knows neither he nor his doctors.

There is a difference in mortality, though not so significant: in the control group died of 11.6% of patients in the experimental — 8%.

If the final results of the study are not much at odds with its interim results, ramdevpir will be the first drug that successfully completed clinical trials against Covid-19.

“we Now have enough data to consider on an emergency basis to allow doctors to use [ramdevpir]”, — wrote in “Twitter” the former head of the office for sanitary supervision over the quality of the food and drug administration Scott Gottlieb.

it is Interesting that literally in the day before the Lancet published the results of another study testing the influence of ramdevpir on coronavirus.

the Experiment was conducted in China and was completed with the opposite result: the effectiveness of the drug failed to prove.

However, experts note that the Chinese study conducted only on 237 patients, is not representative enough to draw such conclusions. The experiment had to end early because of lack of participants.

Nikolay Voronin
reporter for science